Scleroderma, Systemic
Welcome,         Profile    Billing    Logout  
 40 Companies   40 Products   40 Products   47 Mechanisms of Action   2 Trials   213 News 


12345»
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion, Trial primary completion date:  Rituximab in Systemic Sclerosis (clinicaltrials.gov) -  Mar 2, 2018   
    P2/3,  N=22, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> May 2018 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2016
  • ||||||||||  imatinib / Generic mfg.
    Trial completion, Trial primary completion date:  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis (clinicaltrials.gov) -  Feb 6, 2018   
    P2a,  N=30, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2011
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Biomarker, Trial completion:  IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) -  Dec 5, 2017   
    P1/2,  N=21, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  zibotentan (ZD4054) / AstraZeneca
    Trial completion, Enrollment change, Trial primary completion date:  ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) -  Oct 31, 2017   
    P2,  N=27, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=72 --> 27 | Trial primary completion date: Oct 2016 --> Oct 2017
  • ||||||||||  Enrollment change:  CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study (clinicaltrials.gov) -  Aug 30, 2017   
    P=N/A,  N=40, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Dec 2017 N=300 --> 40
  • ||||||||||  Trial completion, Trial primary completion date, IO biomarker:  Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Aug 14, 2017   
    P=N/A,  N=629, Completed, 
    N=300 --> 40 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Psychological Treatments for Scleroderma (clinicaltrials.gov) -  Aug 8, 2017   
    P2,  N=89, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014 No longer recruiting --> Completed
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Trial completion, Trial primary completion date:  Nilotinib in the Treatment of Systemic Sclerosis (clinicaltrials.gov) -  Apr 28, 2017   
    P2a,  N=10, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Biomarker, Enrollment closed, Enrollment change:  IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) -  Mar 30, 2017   
    P1/2,  N=19, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014 Recruiting --> Active, not recruiting | N=40 --> 19
  • ||||||||||  Trial primary completion date, IO biomarker:  Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Jul 19, 2016   
    P=N/A,  N=629, Active, not recruiting, 
    Trial primary completion date: Jan 2016 --> Jan 2018 Trial primary completion date: Mar 2016 --> Sep 2016
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Trial completion:  ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) -  Jul 6, 2016   
    P2,  N=16, Completed, 
    Trial primary completion date: Mar 2016 --> Sep 2016 Active, not recruiting --> Completed
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion, Enrollment change:  SCOT Scleroderma Treatment Alternative Registry (STAR Registry) (clinicaltrials.gov) -  May 19, 2016   
    P=N/A,  N=19, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jun 2016 Active, not recruiting --> Completed | N=45 --> 19
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) -  May 13, 2016   
    P3,  N=14, Terminated, 
    Active, not recruiting --> Completed | N=45 --> 19 N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015
  • ||||||||||  Trial completion:  ESOS: Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) -  May 13, 2016   
    P=N/A,  N=320, Completed, 
    N=75 --> 14 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015 Active, not recruiting --> Completed
  • ||||||||||  fipaxalparant (AMG 670) / Amgen
    Trial primary completion date:  Proof of Biological Activity of SAR100842 in Systemic Sclerosis (clinicaltrials.gov) -  Mar 25, 2016   
    P2,  N=32, Completed, 
    Active, not recruiting --> Completed | N=400 --> 602 Trial primary completion date: Apr 2014 --> Nov 2013
  • ||||||||||  Habeo Cell Therapy (ECCS-50) / Plus Therap
    Enrollment change, Trial withdrawal:  STAR: Scleroderma Treatment With Celution Processed ADRCs Registry (clinicaltrials.gov) -  Mar 18, 2016   
    P=N/A,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=500 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Biomarker, Trial primary completion date:  Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension (clinicaltrials.gov) -  Mar 4, 2016   
    P=N/A,  N=30, Recruiting, 
    Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  cyclophosphamide / Generic mfg.
    Trial completion:  Scleroderma Lung Disease (clinicaltrials.gov) -  Feb 27, 2016   
    P3,  N=158, Completed, 
    Trial primary completion date: Dec 2015 --> May 2016 No longer recruiting --> Completed
  • ||||||||||  acetylcysteine solution / Generic mfg.
    Enrollment change, Trial termination:  A Clinical Trial for CTD-ILD Treatment (clinicaltrials.gov) -  Feb 12, 2016   
    P2/3,  N=5, Terminated, 
    No longer recruiting --> Completed N=20 --> 5 | Recruiting --> Terminated; Departure of study team
  • ||||||||||  sildenafil / Generic mfg.
    Trial completion:  PROFIL: "As Required" Oral Sildenafil in Raynaud's Phenomenon (clinicaltrials.gov) -  Jan 19, 2016   
    P2/3,  N=41, Completed, 
    N=20 --> 5 | Recruiting --> Terminated; Departure of study team Recruiting --> Completed
  • ||||||||||  Trial primary completion date, IO biomarker:  Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Dec 23, 2015   
    P=N/A,  N=629, Active, not recruiting, 
    N=18 --> 9 Trial primary completion date: Sep 2015 --> Mar 2016